Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference
MWN-AI** Summary
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, is set to showcase its pioneering role in total artificial heart therapy at the Technology and Heart Failure Therapeutics (THT) 2026 conference in Boston, from March 2nd to March 4th. Dr. Andre Simon, Vice President of Clinical Affairs, will present three significant talks emphasizing the advancements in artificial heart technologies, including the current SynCardia Total Artificial Heart (STAH) and the next-generation Emperor system, which aims to enhance patient mobility and quality of life.
In his presentations, Dr. Simon will highlight the early successes of the Emperor system, illustrating its potential through preliminary lab and clinical assessments. Key topics will include the future of total artificial heart therapy, focusing on critical factors such as earlier patient intervention, organ recovery, and optimizing transplant eligibility. His presentations seek to redefine the metrics of success beyond mere survival rates to encompass overall quality of life improvements and functional recovery.
The THT 2026 conference serves as a gathering for clinicians, researchers, and industry leaders to engage in discussions around innovative heart failure therapies, regulatory pathways, and clinical strategies. Picard Medical's involvement underlines its commitment to advancing the field of mechanical circulatory support and improving patient outcomes through educational initiatives and collaboration.
SynCardia has established itself as the global leader in total artificial heart technology, with over 2,100 successful implants worldwide, reinforcing its status as the most studied artificial heart system. Picard Medical’s continued investment in research and development aims to push the boundaries of cardiac therapy and offer hope to patients suffering from advanced heart failure. For more details, visit [Picard Medical](http://www.picardmedical.com).
MWN-AI** Analysis
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, is positioning itself as a market leader in total artificial heart therapy, underscored by its presence at the Technology and Heart Failure Therapeutics (THT) 2026 conference in Boston. With the introduction of the next-generation Emperor system and ongoing advancements in the SynCardia Total Artificial Heart (STAH), the company demonstrates its commitment to enhancing clinical outcomes and quality of life for heart failure patients.
Investors should note several key factors influencing Picard Medical's market outlook. First, the company's pioneering role in the total artificial heart sector, being the only one approved by the FDA and Health Canada, offers a significant competitive advantage. This exclusivity is important in addressing the critical patient need for advanced heart failure solutions, which is likely to drive demand and revenue growth.
Dr. Andre Simon's presentations at THT, showcasing early positive results from the Emperor system and emphasizing comprehensive recovery beyond mere survival, reflect Picard's innovative approach. Investors should monitor the clinical outcomes data presented, which could substantiate the efficacy of Picard's solutions, potentially influencing partnerships with healthcare providers and insurers.
Moreover, as the global market for heart failure therapies expands, Picard's focus on technological innovations and clinical advancements aligns well with evolving healthcare trends favoring early intervention and improved patient selection. This proactive approach could position Picard as a frontrunner in future therapeutic developments.
However, potential investors must also consider inherent risks, including market competition and regulatory challenges. The future success of Picard Medical hinges on continued innovation, successful clinical trials, and effective market penetration strategies.
In conclusion, given Picard Medical's strong position and ongoing advancements in heart failure therapy, this company presents an attractive investment opportunity for those looking to participate in the evolving healthcare landscape. Investors should remain vigilant for updates from upcoming presentations and clinical trial results to refine their investment strategy.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs, will deliver three scientific and educational presentations at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston from March 2nd to March 4th 2026. Dr. Simon’s presentations will focus on both the current SynCardia Total Artificial Heart (STAH) and the Company’s next-generation fully implantable Emperor system, reinforcing Picard Medical’s leadership in advanced mechanical circulatory support.
Dr. Andre Simon commented, “Total artificial heart therapy continues to evolve through both clinical experience and technological innovation. Our goal is not only survival, but meaningful recovery, improved quality of life, and preservation of transplant opportunity. Picard Medical’s participation at THT reflects the Company’s ongoing commitment to scientific exchange, physician education, and innovation in next generation artificial heart technology.”
More information on Dr. Simon’s three presentations is below:
Format: Scientific Abstract Presentation
Date and Time: Monday, March 2; 4:15 PM EST; HF Focus Station 2 | Ensemble C-D | Level 2
Title: “The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart”
Dr. Simon will present early laboratory and preclinical data demonstrating that the Emperor system preserves the proven physiologic performance of the SynCardia Total Artificial Heart. The fully implantable architecture is designed to eliminate transdermal pneumatic drivelines and enable improved mobility, quality of life, and long-term patient independence.
Format: Educational Lecture
Date and time: Tuesday, March 3; 3:28 PM EST; Ensemble E-F | Level 2
Title: “The Total Artificial Heart of the Future: My Wish List”
In this invited session, Dr. Simon will discuss the future evolution of total artificial heart therapy, including clinical priorities such as earlier intervention, organ recovery, improved patient selection, and the transition from bridge to transplant toward durable long-term support.
Format: Clinical Outcomes Presentation
Date and Time: Wednesday, March 4; 8:50 AM EST; Ensemble C-D | Level 2
Title: “Beyond Survival: Defining Success After Total Artificial Heart Implantation”
This presentation will highlight updated registry analyses showing that outcomes with the SynCardia Total Artificial Heart extend beyond survival to include stabilization, organ recovery, functional improvement, and preservation of transplant eligibility. Key findings include sustained clinical success in critically ill patients, improved outcomes in patients implanted earlier in their disease trajectory, strong recovery potential even in patients initially not eligible for transplant, and significant improvements in quality of life after early postoperative recovery. Renal and neurological outcomes remain major determinants of long-term success.
About THT 2026
Technology and Heart Failure Therapeutics (THT) 2026 is an international conference focused on advancing innovation in heart failure through emerging device, technology, and combination therapies. Sponsored by the Cardiovascular Research Foundation, THT brings together leading clinicians, researchers, and industry partners to share the latest clinical data, discuss regulatory and commercial pathways, and explore future trends shaping the management of advanced heart failure. The multidisciplinary program features cutting-edge scientific sessions, case-based discussions, and hands-on training designed to foster collaboration and improve patient outcomes. For more information, visit https://www.thtmeeting.com/about-tht.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to address the clinical priorities for total artificial heart therapy, as discussed by Dr. Andre Simon during his presentation at the THT 2026 conference?
What key findings from Dr. Simon's presentation on clinical outcomes suggest that the SynCardia Total Artificial Heart by Picard Medical Inc. PMI can improve long-term patient independence?
In what ways does the next-generation Emperor system from Picard Medical Inc. PMI aim to enhance patient mobility and quality of life compared to the current SynCardia Total Artificial Heart?
How does Picard Medical Inc. PMI intend to leverage scientific exchanges and educational initiatives highlighted by Dr. Simon at THT 2026 to sustain its leadership in advanced mechanical circulatory support?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
11.56% G/L:
$1.205 Last:
66,661 Volume:
$1.14 Open:
